---  
layout: startup_page  
title: "Asceneuron SA"  
id: "asceneuron.com"  
permalink: "/asceneuronsaasceneuron.com07162024/"  
website: "https://www.asceneuron.com/"  
funding_round: "Series C"  
funding_amount: "$100M"  
investors: "Novo Holdings, EQT Life Sciences - LSP Dementia Fund, OrbiMed, SR One, M Ventures, Sofinnova Partners, GSK Equities Investments Limited, Johnson & Johnson Innovation - JJDC, Inc"  
about: "Asceneuron SA is a clinical-stage biotech company developing small molecules targeting tau protein aggregation, a root cause of neurodegenerative diseases. Their lead asset, ASN51, is an oral small molecule OGA inhibitor designed to slow the progression of Alzheimer's disease by preventing tau protein aggregation. The company is advancing ASN51 into Phase 2 clinical development."  
markets: "Biotechnology, Pharmaceuticals, Alzheimer's Disease, Neurodegenerative Diseases"  
hq: "Lausanne, Vaud, Switzerland"  
founded_year: "2012"  
linkedin: "https://www.linkedin.com/company/asceneuron-sa"  
twitter: "https://twitter.com/asceneuron_sa"  
instagram: ""  
facebook: ""  
crunchbase: "https://www.crunchbase.com/organization/asceneuron"  
pitchbook: "https://pitchbook.com/profiles/company/64606-24"  

date_display: "16-Jul-2024"  
date: "2024-07-16"

# SEO Optimization  
meta_title: "Asceneuron SA - Series C Funding ($100M)"  
meta_description: "Asceneuron SA, Asceneuron SA is a clinical-stage biotech company developing small molecules targeting tau protein aggregation, a root cause of neurodegenerative dise..."  
meta_keywords: "Asceneuron SA, Biotechnology, Pharmaceuticals, Alzheimer's Disease, Neurodegenerative Diseases, Series C funding"  
canonical_url: "https://startup.projectstartups.com/asceneuronsaasceneuron.com07162024/"  
---